TherapeuticsMD falls as FDA rejects revisions to co's birth-control drug production

TherapeuticsMD

10/12/2021 22:35

** Shares of women's healthcare co  TXMD.O  down ~5% to 43
cents in extended trading 
    ** U.S. FDA says it could not approve revisions to certain
manufacturing testing limits for co's birth control drug
Annovera  urn:newsml:reuters.com:*:nBw7CpRr4a
    ** Annovera is a reversible birth control method that
prevents ovulation for a year 
    ** TXMD says it will continue to manufacture and supply
Annovera under currently approved specifications 
    ** TXMD down ~63% YTD

 (Reporting by Nathan Gomes in Bengaluru)
 ((Nathan.Gomes@thomsonreuters.com;))